SI
MDGL icon

Symmetry Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

Symmetry Investments’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,500
Closed -$1.1M – 225
2023
Q3 		$1.1M Hold
7,500
– – 0.22% 91
2023
Q2 		$1.73M Buy
+7,500
New +$2.03M 0.26% 77

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Symmetry Investments's MDGL Position: Q2 2024 in Review

Symmetry Investments sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 1,500 shares — an estimated $401K sold.

Symmetry Investments first reported a position in MDGL in Q3 2023 and held it in 2 quarters. The position peaked at $401K in Q1 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

  • Symmetry Investments reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Symmetry Investments sold 1,500 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $401K.
  • Symmetry Investments first reported a position in Madrigal Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Symmetry Investments's Madrigal Pharmaceuticals position peaked at $401K in Q1 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on Symmetry Investments's 13F filing for Q2 2024, filed 13 Aug 2024.